

REMARKS

Formal Matters

The present application has been amended to insert the Sequence Listing.

No new matter is added.

Certification Regarding Sequence Listing

I hereby certify that the enclosed Sequence Listing is being submitted under 37 CFR §§ 1.821(c) and (e) in paper and computer readable form (Compact Disk labeled 'CRF').

As required by 37 CFR 1.821(f), I hereby state that the content of the paper and computer readable copy of the Sequence Listing, submitted in accordance with 37 C.F.R. §1.821(c) and (e) are the same. The Computer Readable Format (CRF), being submitted under 37 CFR §§ 1.52(e) and 1.824, is formatted on IBM-PC, the operating system compatibility is MS-Windows and the file listing is:

Seqlist.txt 4.06 KB created December 30, 2002.


I hereby certify that the enclosed submission includes no new matter. The Sequence Listing was prepared with the software FASTSEQ, and conforms to the Patent Office guidelines. Applicant respectfully submits that the subject application is in adherence to 37 CFR §§ 1.821-1.825.

Respectfully submitted,

Dated: _____

Jan. 6, 2003

By: _____



Paula A. Borden
Registration No. 42,344

BOZICEVIC, FIELD & FRANCIS LLP
200 Middlefield Road, Suite 200
Menlo Park, CA 94025
Telephone: (650) 327-3400
Facsimile: (650) 327-3231

“Version with Markings to Show Changes”

Please replace the paragraph on page 13, starting at line 9 with the following paragraph:

A subject fusion protein may comprise, in addition to a fusion partner polypeptide and a ubiquitination-regulating polypeptide, an immunological tag. An immunological tag, if present, is present at the amino terminus, the carboxyl terminus, or disposed between the fusion partner polypeptide and the metal ion affinity peptide. Immunological tags are known in the art, and are typically a sequence of between about 6 and about 50 amino acids that comprise an epitope that is recognized by an antibody specific for the epitope. Non-limiting examples of such tags are hemagglutinin (HA; e.g., CYPYDVDPYA, SEQ ID NO: 2), FLAG (e.g., DYKDDDDK, SEQ ID NO: 3), c-myc (e.g., CEQKLISEEDL, SEQ ID NO: 4), and the like.

Please replace the paragraph on page 25, starting at line 11 with the following paragraph:

Materials and Methods

Plasmid and Vector Construction. Full-length human TSG101 cDNA was inserted into the pLLEXP1 vector (1) between the cytomegalovirus promoter and polyadenylation site. HA-tagged (human influenza hemagglutinin peptide, YPYDVDPY, SEQ ID NO: 5), Flag-tagged and c-Myc tagged TSG101 and TSG101 deletion mutant cDNAs were generated by PCR and were also cloned using pLLEXP1. Vectors expressing human wild type p53 (pC53-SN3) (25), human mutant p53 (pC53-Cx21an3, aa 175 mutation, Arg to His) (26), human MDM2 (pCHDM1B) (27), and HM-Ub and HM-K48R-Ub (28) have been described. pCMV-GFP (Clontech) was used to express green fluorescent protein (GFP).